BioAge Labs UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, everybody. Welcome to the next session at the UBS Biopharma Conference in London. I am Alice Nettleton, one of the senior biotech analysts at UBS. To introduce BioAge Labs, we have with us BJ Sullivan, Chief Strategy Officer. BJ, thank you so much for joining us. Maybe to start with, for those who are less familiar with this story, would you like to give a brief overview of BioAge and where you are at right now?
Happily, and thank you for having us here. Quite a way to kick off London Biotech Week. Thank you to all of you who are attending in person. I recognize, we are probably the one thing standing between you and cocktails, so appreciate it. BioAge is a platform company. We are harnessing the biology of human aging to identify promising targets for cardiometabolic disease. Our lead program is BGE-102. It is an oral potential best-in-class NLRP3 inhibitor, and we released phase I data in April this year showing we are able to achieve up to 98% trough inhibition of IL-1β with placebo-like tolerability and a really exceptional tissue distribution profile that enables us to address inflammation in any compartment of the body.
We have an ongoing phase II trial right now called QUELL-CV, where we are testing three doses of BGE-102 and trying to understand the dose response relationship between obviously dose and degree of IL-1β suppression and a rich set of inflammatory and metabolic markers. We are really trying to tease that apart and understand the tolerability as well as the effect of these biomarkers over a three-month treatment period. We think that is going to be a very rich data set. We are targeting data, committed to data at the end of this year. We also have the QUELL-DME proof of concept trial in diabetic macular edema. This is really our beachhead into ophthalmology, and it is enabled by this tissue distribution profile that gives very high free drug in the retina.
This trial is looking at BGE-102 both as a monotherapy as well as in combination with VEGF in diabetic macular edema over three months of treatment, and we are powered for about a line of improvement in BCVA. We are very excited about that ongoing trial, and that is reading out at the end of next year. That is our lead program. We are also developing 2 APJ agonists, so we are developing both an oral and a parenteral version. This is a target that in our cohort is among the most highly associated with both longevity as well as preservation of physical function, so we are very excited to be back in the clinic with this target.
We're guiding to filing our IND for the first APJ agonist program by the end of this year, and we're very excited at that time to really debut the program and talk in more detail about our clinical development strategy. This is something that has the potential, at least in preclinical models, to double weight loss and completely restore body composition in obesity. I'm happy to talk further about that later.
Great. Thank you so much. Maybe we can start with BGE-102 in ASCVD. It's an NLRP3 inhibitor. Obviously, there's some other NLRP3 inhibitors in development, and there's the NEK7. Can you talk a little bit about your differentiation? I think you have a novel binding site.
Right. What advantages do you think this may confer in the clinic compared to others?
NLRP3 is a target that has been prosecuted now for decades. A lot of it is, Pfizer brought the first one into the clinic two decades ago, and a lot of other approaches to targeting NLRP3 are essentially derivatives of that chemotype or novel chemotypes targeting the same binding site, which is the ATPase pocket. We decided to take a totally de novo approach. We did it at DEL screen. We blocked that binding site. We were intentionally looking for novel binding and optimizing the profile really for brain penetration and tissue sort of distribution that was suboptimal in sort of historical programs. We've done very detailed characterization of this binding site with Matthias Geyer at the University of Bonn, who's really an expert in crystallizing the NLRP3 protein.
Part of this characterization is really what we've shown is that we're able to both inhibit assembly of the inflammasome as well as trigger the disassembly of the inflammasome. As it goes from a monomer to a decamer and these different states of activation, we're able to inhibit it. That may explain why we're able to achieve such profound reductions in IL-1β. In our phase I trial, with the 120 milligram dose, what we saw was essentially 98% trough suppression. At the end of the 24-hour period, meaning you get almost, like, pretty much complete target inhibition for that full 24 hours. That, we think we're really differentiated in the depth of that target inhibition, which may be explained by that binding site.
Great. There are a lot of indications that could potentially be addressed by NLRP3. What indications do you think your asset is most suited to? I guess for the CNS penetration- Yes.
Right. You're going after DME, but Right.
So, I think to just give everyone a little bit of context, NLRP3 is really a mediator of sterile inflammation in the body. As opposed to an innate immune response to a pathogen, NLRP3 is activated in response to a lot of sterile stress signals. So, that can be metabolic stress, it can be hyperglycemia, oxidized LDL, cholesterol crystals. That is why you see it very highly associated with cardiometabolic disease. So, there are a broad range of indications that we feel like we can address with this target. DME is one where we really feel we are able to take advantage of this tissue distribution profile. Again, we get very high free levels in the retina, so we can address a disease that is known to be driven, at least in part, by inflammation, in a very convenient dosing format.
But we are also able to address, we think, the sort of the systemic disease phenotype, right? So, hyperglycemia and diabetes causes metabolic stress throughout the body. It causes systemic inflammation. So, when we are treating DME, we are able to address, we think, the systemic disease as well, right? So that there are benefits for broad metabolic benefits in addition to directly targeting the DME pathology specifically.
We recently saw the full ZEUS data at AHA, which is Novo's IL-6 ziltivekimab. Can you walk us through your thoughts on that and what data points helped clarify kind of the reason for this trial failing and the key implications for BGE-102?
Right. So, maybe to set some context, we know that intervening and targeting inflammation can result in MACE benefit in cardiovascular disease. So, colchicine, which is an indirect NLRP3 inhibitor, has quite meaningful MACE benefits in certain patient populations. We saw in the CANTOS trial with canakinumab that targeting IL-1 beta can result in very meaningful MACE benefits. So, we were surprised, certainly, when ZEUS read out with a hazard ratio of about one, right? So, this is targeting IL-6, which is a downstream cytokine. Going into the AHA presentation, I think there were basically two hypotheses. One is that the population enrolled here, which was ASCVD and comorbid CKD, was too far gone. The disease was too severe, and the risk wasn't modifiable at that stage. The other hypothesis was that IL-6 is too far downstream. So, you have inflammation, like NLRP3 is activated at the plaque.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
